Evogene Ltd. · NASDAQ:EVGN
Evogene — Investor Presentation (May 2024)
43 slides from Evogene's investor presentation, May 2024
Slide 1: Pioneering Life-Science Products
PIONEERING Life-Science Products OFER HAVIV | PRESIDENT & CEO May, 2024
Slide 2: Forward-looking statements
This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the “Company”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are co
Slide 3: Agenda
AGENDA About Evogene Value Proposition Business Strategy Success Stories Summary 3
Slide 4: Desire for Progress & a Better Future
Throughout History HUMANS HAVE CONSISTENTLY INVESTED TIME AND RESOURCES IN THE PURSUIT OF IMPROVING LIFE, WELL-BEING, AND HEALTH, FUELED BY AN INNATE DESIRE FOR PROGRESS & A BETTER FUTURE 4
Slide 5: Our Decoding Biology
DECODING BIOLOGY OUR PIONEER GROUNDBREAKING LIFE- SCIENCE PRODUCTS ROOTED IN MICROBES, SMALL MOLECULES, AND GENOMICS 5
Slide 6: Microbes, Small Molecules, Genetic Elements
MICROBES SMALL MOLECULES GENETIC ELEMENTS Microbials Therapeutic Crop Pharmaceuticals Medical for crops microbials protection Alternative Cannabis food Chemical Gene Food stimulants Advanced therapy wound care Improved Dietary crops supplements Animal Cell fertility therapy Human & Medical animal de
Slide 7: Product Development in Life Science
Pharma Ag-chemicals Industry Industry Cost of developing a single Years to develop a new crop pharmaceutical drug* protection product** OF LIFE SCIENCE 1995 8Y In the 1970’s PRODUCT $180M 2000 DEVELOPMENT 9Y Low probability of success 2005-2008 with high cost and long In recent years 10Y > $2,000M t
Slide 8: Life-Science Products Long-Tail Process
LIFE-SCIENCE PRODUCTS LONG-TAIL PROCESS THE finding the winning candidates out of a vast number of possible prospects that CHALLENGE address a complex myriad of criteria, to reach higher success rate for products > DISCOVERY > OPTIMIZATION > DEVELOPMENT > REGULATION “Needle in the Approved haystack”
Slide 9: On the Brink of a Big Life-Science Data Revolution
TODAY WE ARE ON THE BRINK OF A BIG LIFE- AI DATA SCIENCE Computational technology advancements enable the LIFE-SCIENCE PRODUCT DEVELOPMENT discovery and optimization of the most promising candidates, addressing multiple development challenges towards successful life-science based products Accelerati
Slide 10: Our Decoding Biology
OUR DECODING BIOLOGY WE MERGE LIFE-SCIENCE WITH BIG DATA AND CUTTING- EDGE AI TECHNOLOGIES TO EFFECTIVELY DISCOVER AND OPTIMIZE BREAKTHROUGH LIFE-SCIENCE BASED PRODUCTS 10
Slide 11: Evogene at a Glance
ISRAEL 2002 EVGN 135 30% 50% HQ Established NASDAQ Employees PhD’s Woman & TASE 3 4 COMMERCIAL Innovative AI Subsidiaries PRODUCTS* Tech Engines Bio-inoculant Castor varieties Microbes Genetic Elements Ag Biologicals Microbiome-based EVF701 Therapeutics EVF712 Small Molecules Ag Chemicals Castor Cul
Slide 12: Investors and Collaborators
& Group Investment & Investment & Collaboration Collaboration Collaboration Collaboration Collaboration Collaboration Collaboration Collaboration Collaboration Investment Collaboration 12
Slide 13: Agenda
AGENDA About Evogene Value Proposition Business Strategy Success Stories Summary 13
Slide 14: Breakthrough Products Backed by Technology & Science
Breakthrough Products Backed by Technology & Science PLATFORM SCIENCE Born from over a decade of intensive R&D, fueled by millions of dollars in investment, BIG DATA AI merging life-science with big- data and cutting-edge AI technology, the CPB directs and accelerates life-science product discovery
Slide 15: The Result: Direct and Accelerate Product Development
WE DIRECT AND ACCELERATE LIFE-SCIENCE PRODUCT & utilizing 3 dedicated AI tech-engines MICROBES The Result: Promising candidates addressing multiple development challenges towards successful SMALL life-science-based products. MOLECULES GENETIC PROBABILITY TIME COST ELEMENTS OF SUCCESS 15
Slide 16: AI Tech-Engines
AI TECH- ENGINES Discovery Direct & accelerate life-science product discovery & optimization Computational selection of the most promising candidates to initiate the product development process. Optimization Computational driven solution addressing optimization challenges for the selected candidates
Slide 17: AI Tech-Engine Dashboard
Al TECH-ENGINE DASHBOARD (Example) 200,599,577 ey me FES memnanenainanaan — LB ensappntcnine a Micro S2/300st*! evOgene 17
Slide 18: Potential Markets for MicroBoost AI
Potential Markets for MicroBoost AI (Example) MARKET DIVERSITY Microbials Therapeutic for crops microbials Food Probiotics Structuring an ’ecosystem’ of diverse product types to be Human & animal Dietary supplements developed utilizing our probiotics AI Tech-Engines Waste-water Plastic treatments de
Slide 19: Agenda
AGENDA About Evogene Value Proposition Business Strategy Success Stories Summary 19
Slide 20: Microbes, Small Molecules, Genetic Elements
MICROBES SMALL MOLECULES GENETIC ELEMENTS Microbials Therapeutic Crop Pharmaceuticals Improved Medical for crops microbials protection crops Cannabis Chemical Advanced Alternative Gene Food Probiotics stimulants wound care food therapy Animal Cell healthcare therapy Human & Dietary Medical device an
Slide 21: Maximum Potential, Minimum Risk
MAXIMUM POTENTIAL MINIMUM Capture the value of our AI tech-engines RISK through diverse collaborative partnerships to accelerate life-science product development Partnering with experts in specific fields complements our technology, enabling groundbreaking innovations and financial gains for Evogene
Slide 22: Licensing and Collaboration
Capture the value of our AI tech-engines as product-development enablers, through: LICENSING COLLABORATION A time-limited license grant for utilizing Joint product development with a one of Evogene’s tech-engines, to a leading company utilizing related party for product development Evogene’s unique
Slide 23: Licensing Business Model
01 Business Model Licensing License fees & R&D reimbursement Royalties from sale of end-products Dividends to Evogene as a shareholder* Significant one-time-payment upon an exit event** Powered by *Subject to meeting the Israeli dividend tests and criteria. May no be distributed in the near
Slide 24: Collaboration Business Model
02 Business Model Collaboration Upfront payments R&D fees Milestone payments Royalties from sale of end-products Powered by 24
Slide 25: Current Status
CURRENT STATUS Licensing Collaboration MICROBES SMALL MOLECULES GENETIC ELEMENTS Therapeutic microbials Crop protection Castor for bio-based industries • Immuno-oncology program • Herbicides • Elite castor seed varieties • GI related disorders • Fungicides • Insecticides Food-tech Microbials for cro
Slide 26: Agenda
AGENDA About Evogene Value Proposition Business Strategy Success Stories Summary 26
Slide 27: Lavie Bio Mission
MISSION Evogene’s Improve food quality, sustainability and agricultural productivity Subsidiary through microbiome-based, ag-biological products AG-BIOLOGICALS UNIQUE AI BROAD & STRATEGIC 2 REVENUE- A RAPIDLY TECH-PLATFORM DIVERSE INVESTORS & GENERATING GROWING AND DATA ASSETS PIPELINE PARTNERS GRAD
Slide 28: Yalos Bio-inoculant Yield Improvement
Powered by Evogene’s Yalos | Bio-inoculant for cereal grains* Subsidiary SOLD IN USA & CANADA** SUPERIOR PERFORMANCE CONSISTENT PERFORMANCE & expanding globally vs. alternatives 6% Check Yield improvement (%) 5% 4% 3% 2% 1% Other Ag-biologicals Control * Yalos has regulatory approval in the US & Can
Slide 29: MicroBoost AI Tech-Engine
MICROBOOST AI TECH-ENGINE Powered by Evogene’s directing & accelerating product Subsidiary discovery & optimization Computational analysis of DB Powered by Experimental validation Commercial viability and optimization ~100,000 5% success Bacterial computational Bacterial teaming by function stra
Slide 30: Casterra Mission
Mission Evogene’s To provide an integrated solution for Industrial cultivation of castor Subsidiary for bio-based industries UNIQUE TECH CASTOR OIL - INTEGRATED STRATEGIC PLATFORM FOR COMMERCIAL EMERGING MARKET AG-SOLUTION ALLIANCE ELITE SEED PRODUCTS VARIETIES A sustainable energy Combining deep sc
Slide 31: EVF716, EVF712, EVF701 Elite Castor Varieties
Powered by Evogene’s EVF716, EVF712, EVF701 Subsidiary Elite Castor Varieties $9.1 Million 31
Slide 32: Generator AI Tech Engine
GENERATOR AI TECH ENGINE Powered by Evogene’s directing & accelerating product Subsidiary discovery & optimization Breeding programs of varieties suitable for mechanized harvest High-throughput Powered by genetic screening for Genetic high yield & oil traits diversity ~200 * Powered by WW germplasm
Slide 33: Agenda
AGENDA About Evogene Value Proposition Business Strategy Success Stories Summary 33
Slide 34: Vision, Mission, Offering
VISION Pioneer groundbreaking life-science MAXIMUM POTENTIAL, MINIMUM RISK products rooted in microbe, small molecule, and genomics innovations. EVOGENE PARTNER AI Tech Specific Engines Expertise MISSION Novel Life-Science PRODUCT We merge scientific expertise with cutting-edge AI and big data techn
Slide 35: Thank You
~ > YOON + 1 * WS CH | x HUM. etn. , LTR : + UTP ANS 0
Slide 36: Annex I: Financial Overview
FINANCIAL OVERVIEW evVegene
Slide 37: Balance Sheet Key Points
Thousands of US $ 31.03.2024 31.12.2023 Key Points: Current Assets 31,022 34,469 Consolidated cash position: ~$26.6 million as of 31.03.2024 Long-Term Assets 15,758 16,632 No bank debt Total Assets 46,780 51,101 Current Liabilities 6,129 6,944 Long-Term Liabilities (inc. ~$10m convertible SAFE a
Slide 38: Income Statement Key Points
Thousands of US $ 1-3/2024 1-3/2023 Revenues 4,190 641 Key Points: Cost of revenues 310 322 Q1 2024 revenue: $4.2M vs. $0.6M in Q1 2023; anticipating continued growth in 2024. Gross profit 3,880 319 Q1 2024 net loss: $3.8M vs. $7.0M in Q1 2023. Research and development. net 4,801 4,800 Project
Slide 39: Annex II
Annex II
Slide 40: Expected Value Drivers: Casterra
Powered by Expected Value Drivers CASTOR OIL PRODUCTION Expanding the seed production operations in several CASTERRA’S MISSION: sites in Africa & Latin America, to fulfill all existing orders To provide an integrated solution for industrial cultivation of castor for bio-based industries Strategic al
Slide 41: Expected Value Drivers: Lavie Bio
Powered by Expected Value Drivers Ag Biologicals BIO-PESTICIDES LAVIE BIO’S MISSION: Improve food quality, sustainability and LAV311 - US regulatory approval for bio-fungicide candidate for fruit rots – expected by 2024 agriculture productivity through microbiome based, AI-driven, ag-biological prod
Slide 42: Expected Value Drivers: Biomica
Powered by Expected Value Drivers Human Microbiome BIOMICA’S MISSION: IMMUNO-ONCOLOGY Discovery and development of novel microbiome- Readout & completion of POC from first in-human based therapeutics for human disorders, study in 2024 utilizing cutting edge computational capabilities Initiation of p
Slide 43: Expected Value Drivers: AgPlenus
Powered by Expected Value Drivers AG-CHEMICALS HERBICIDES AGPLENUS’ MISSION: Design next-generation, effective, and Corteva collaboration - achieve 2nd milestone sustainable crop protection products by Bayer collaboration - design additional molecules leveraging predictive chemistry and biology FUNG